GSK falls as blood cancer drug likely headed for US rejection

GSK (GSK.L), shares fell more than 6% on Friday to the bottom of Britain’s blue-chip index after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over side effects.